Harry Copping

Despite ADC’s raging success in oncology in the clinic, translational barriers still plague ADC development, with preclinical activity not matching early clinical safety and efficacy readouts and therapeutic index

As the field turns its attention to advance novel conjugate translation, join your peers to best leverage preclinical tools and understand rationale to effectively characterise safety and efficacy to minimise the ADC translational mismatch

Workshop highlights include:

• Gleaning insights from PDX models alongside emerging capabilities and challenges from in vitro and organoid models
• Understanding translational considerations for novel conjugates including bispecific ADCs and combination therapies
• Delving into in vitro pharmacology studies with high content imaging to better understand ADC trafficking, favourable design characteristics and considerations for nonspecific uptake